President Trump’s preferred coronavirus treatment is the focus of a new study suggesting it could cause more harm than good, but not everybody agrees. We discuss the fallout as trials around the world are paused and countries diverge over policy advice.
12:12 Are we rushing science?
Coronavirus papers are being published extremely quickly, while normally healthy scientific debate is being blown up in the world’s press. Is there a balancing act between timely research and accurate messaging?
18:49 One good thing
Our hosts pick out things that have made them smile in the last week, including hedgerow brews and a trip into the past using AI.
Interview with Dr. Nicole Lurie on rapid vaccine development, including new tools to facilitate vaccine testing and manufacturing and persistent challenges.
The need to rapidly develop a vaccine against SARS-CoV-2 comes at a time of explosion in basic scientific understanding, including in areas such as genomics and structural biology, that is supporting a new era in vaccine development. Over the past decade, the scientific community and the vaccine industry have been asked to respond urgently to epidemics of H1N1 influenza, Ebola, Zika, and now SARS-CoV-2. An H1N1 influenza vaccine was developed relatively rapidly, largely because influenza-vaccine technology was well developed and key regulators had previously decided that vaccines made using egg- and cell-based platforms could be licensed under the rules used for a strain change. Although a monovalent H1N1 vaccine was not available before the pandemic peaked in the Northern Hemisphere, it was available soon afterward as a stand-alone vaccine and was ultimately incorporated into commercially available seasonal influenza vaccines.
Nicole Lurie is a strategic advisor to the CEO of the Coalition for Epidemic Preparedness Innovations. Stephen Morrissey, the interviewer, is the Executive Managing Editor of the Journal.
Online News Editor David Grimm talks with producer Joel Goldberg about the unique challenges of reopening labs amid the coronavirus pandemic. Though the chance to resume research may instill a sense of hope, new policies around physical distancing and access to facilities threaten to derail studies—and even careers.
Despite all the uncertainty, the crisis could result in new approaches that ultimately benefit the scientific community and the world. Also this week, Joel Podgorski, a senior scientist in the Water Resources and Drinking Water Department at the Swiss Federal Institute of Aquatic Science and Technology, joins host Sarah Crespi to discuss the global threat of arsenic in drinking water. Arsenic is basically present in all rocks in minute amounts. Under the right conditions it can leach into groundwater and poison drinking water. Without a noticeable taste or smell, arsenic contamination can go undetected for years. The paper, published in Science, estimates that more than 100 million people are at risk of drinking arsenic-contaminated water and provides a guide for the most important places to test.
Predicting the path ahead has become nearly impossible, but we can speculate about the size and scale of the economic shock. Economic contagion is now spreading as fast as Covid-19 itself. Social distancing, intended to physically disrupt the spread, has severed the flow of goods and people, stalled economies, and is in the process of delivering a global recession.
Predicting the path ahead has become nearly impossible, as multiple dimensions of the crisis are unprecedented and unknowable. Pressing questions include the path of the shock and recovery, whether economies will be able to return to their pre-shock output levels and growth rates, and whether there will be any structural legacy from the coronavirus crisis.
This Explainer explores several scenarios to model the size and scale of the economic shock and the path ahead.
Based on the HBR article by Philipp Carlsson-Szlezak, Martin Reeves and Paul Swartz
Airlines have strained to survive after travel dried up because of the coronavirus pandemic. WSJ’s Alison Sider explains how airlines are adjusting, and the CEO of Southwest Airlines paints a picture of what the future of flying might look like.
Colin Cowherd talks with Dr. Patrick Soon-Shiong who is not only a Doctor helping to fight Covid-19 but also owns the LA Times and is a minority owner of the Lakers. Dr. Shiong talks about the things we are learning about the disease and why it is so much more dangerous than previous pandemics.
Dr Patrick Soon-Shiong is a South African-American billionaire surgeon, businessman, media mogul, and bioscientist. He is the inventor of the drug Abraxane, which became known for its efficacy against lung, breast, and pancreatic cancer.